期刊
JOURNAL OF CLINICAL INVESTIGATION
卷 120, 期 1, 页码 41-50出版社
AMER SOC CLINICAL INVESTIGATION INC
DOI: 10.1172/JCI41004
关键词
-
资金
- National Cancer Institute, NIH [1RO1CA113796, 1RO1CA138231, 2P50CA093683-06A20006]
- National institute of Neurological Disorders and Stroke, NIH [1KO8NS051349]
- American Heart Association
- NATIONAL CANCER INSTITUTE [R01CA113796, R01CA138231, P50CA093683] Funding Source: NIH RePORTER
- NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [K08NS051349] Funding Source: NIH RePORTER
Cancer stem cells (CSCs) are a subpopulation of tumor cells that selectively possess tumor initiation and self-renewal capacity and the ability to give rise to bulk populations of nontamorigenic cancer cell progeny through differentiation. As we discuss here, they have been prospectively identified in several human malignancies, and their relative abundance in clinical cancer specimens has been correlated with malignant disease progression in human patients. Furthermore, recent findings suggest that clinical cancer progression driven by CSCs may contribute to the failure of existing therapies to consistently eradicate malignant tumors. Therefore, CSC-directed therapeutic approaches might represent translationally relevant strategies to improve clinical cancer therapy, in particular for those malignancies that are currently refractory to conventional anticancer agents directed predominantly at tumor bulk populations.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据